Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSD
Dates
study started
completion around

Description

Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of therapeutic vaccination with chimpanzee adenovirus ChAdOx1- and poxvirus modified vaccinia Ankara (MVA)-vectored conserved mosaic T-cell vaccines in a sequential regimen with the toll-like receptor 7 (TLR7) agonist vesatolimod (VES) and two broadly neutralizing antibodies (bNAbs) compared to placebo, to induce HIV-1 control during analytic treatment interruption (ATI).

Official Title

A Phase I/IIa Randomized, Placebo-Controlled Trial of Conserved-Mosaic T-cell Vaccine in a Regimen With Vesatolimod and Broadly Neutralizing Antibodies in Adults Initiated on Suppressive Antiretroviral Therapy During Acute HIV-1

Details

Keywords

HIV-1-infection, Suppressive Antiretroviral Therapy, HIV, Acute HIV-1, HIV vaccine, T-cell vaccine, Therapeutic T-cell vaccine, ChAdOx1, MVA, Conserved region vaccine, HIVconsvX, Toll-like receptor 7 agonist, TLR7, Broadly neutralizing antibody, Antibodies, HIV antibody, HIV Broadly neutralizing antibody, Vesatolimod, ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES)

Eligibility

Locations

  • University of California, San Diego AntiViral Research Center CRS accepting new patients
    San Diego California 92103 United States
  • Houston AIDS Research Team CRS accepting new patients
    Houston Texas 77004 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
ID
NCT06071767
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 45 study participants
Last Updated